X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    FDA Accepts BLA for Recommended

    FDA Accepts BLA for Recommended Biosimilar to Simponi

    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    FDA Accepts BLA for Recommended

    FDA Accepts BLA for Recommended Biosimilar to Simponi

    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Insights

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2016 Financial Results

Yuvraj_pawp by Yuvraj_pawp
19th January 2017
in Insights

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Vanda Pharmaceuticals Inc announced it will release results for the fourth quarter of 2016 on Wednesday, February 15, 2017, after the market closes.           

Vanda will host a conference call at 4:30 PM ET on Wednesday, February 15, 2017, during which management will discuss the fourth quarter and full year 2016 financial results and other corporate activities. To participate in the conference call, please dial 1-888-771-4371 (domestic) or 1-847-585-4405 (international) and use passcode 44159815.


The conference call will be broadcast simultaneously and archived on Vanda’s website, www.vandapharma.com. Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.


A replay of the call will be available on Wednesday, February 15, 2017, beginning at 7:00 PM ET and will be accessible until Wednesday, February 22, 2017, at 11:59 PM ET. The replay call-in number is 1-888-843-7419 for domestic callers and 1-630-652-3042 for international callers. The passcode number is 44159815.


ABOUT VANDA PHARMACEUTICALS INC.:

Vanda is a specialty pharmaceutical company focused on the development and commercialization of novel therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com.

 

Investor Contact:
Jim Kelly
Senior Vice President & Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
jim.kelly@vandapharma.com

 

Previous Post

Lilly and CoLucid Pharmaceuticals Announce Agreement for Lilly To Acquire CoLucid

Next Post

Jitsubo and Japanese pharma company Enter License Agreement and Collaboration for cardiovascular disease

Related Posts

Strategies for the Resilient Perinatal
Insights

Strategies for the Resilient Perinatal Drug Supply Chain

21st July 2025
Emerging Oral Small Molecule Drugs
Drug Development

Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

21st July 2025
Role of CDMOs In Technology Transfer From Molecule To Market
Insights

Role of CDMOs In Technology Transfer From Molecule To Market

19th June 2025
CDMOs Driving Agile Production Within Intricate Therapies
Insights

CDMOs Driving Agile Production Within Intricate Therapies

19th June 2025
Regulatory Trends in Pharma
Insights

Regulatory Trends in Pharma Manufacturing to Watch in 2025

29th May 2025
Pharmaceutical-Chemicals Market Booms with Rising API Demand
Asia

Pharmaceutical Chemicals Market Booms with Rising API Demand

28th May 2025
Next Post

Jitsubo and Japanese pharma company Enter License Agreement and Collaboration for cardiovascular disease

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In